Archive | Next Phase Archive RSS feed for this section

Dear Europe (V3.)

21 Mar

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

On March 25th, LSN will hold the inaugural RESI Europe life science partnering conference.  Please review the program guide below, which showcases the dozens of senior investors speaking on RESI’s panels, and the startup finalists who are bringing their novel technologies to RESI’s Innovation Challenge and Pitch Challenge.

RESI is a dedicated early stage investor and channel partner conference. The event is cross silo, and brings together investors and strategic partners seeking drugs, devices, diagnostics, and digitals health technologies.  RESI is unique in that we have a one-to-one investor to fundraising CEO dynamic.

If you want to participate in the first ever RESI Europe, there’s still time to register online and participate in RESI Partnering.  We are looking forward to seeing you in Vienna on Monday.

RESI Europe Innovators‘ Pitch Challenge Finalists Announced

21 Mar

By Claire Jeong, Director of Research, Asia BD, LSN

claireOur next RESI will be landing in Vienna in just 4 days, and we are excited to announce the 5 Europe Innovators’ Pitch Challenge finalists for our inaugural Europe conference! These early-stage companies have been selected to present a short pitch to a panel of investor judges, who will provide these companies with constructive feedback.

First introduced in RESI Boston last year (September 2018), the Pitch Challenge has become a unique opportunity for the earliest stage companies, especially those who have had minimal experience in pitching and getting in front of investors. By hearing from investors and key industry partners who actively source and evaluate early-stage technologies, companies are able to improve on their pitches and work on areas of improvement more efficiently.

The Europe Innovators’ Pitch Challenge will run from 1:00 – 2:30 pm on the day of RESI and all attendees are welcome to participate as part of the audience. We look forward to seeing you there!

Moderated by Greg Mannix, VP of International Business Development at Life Science Nation, the investor panelists are:

  • Iris Öhrn, Investment Advisor – Life Sciences & Healthcare, Business Region Göteborg AB
  • Benedikt Luhmann, Principal, VI Partners
  • Andreas Jurgeit, Partner, Lundbeckfonden Emerge
  • Evan Castiglia, Principal, Philips Health Technology Ventures

And last but not least, the finalists are:

Revax

Revax is delivering revolutionary new vaccines for respiratory infections.
2019 scientific publications show that vaccines delivered to the lungs are highly effective being more effective than traditional injection vaccines and provide broader cross-reactive and long-lasting protection. Bringing together key players in aerosol delivery, academic excellence in vaccines, industrial support and clinical research organisation expertise, Revax promises to deliver a revolution in vaccination.
Advantages
* More amenable to use in children and the elderly
* Cross protective, valuable for seasonal changes in influenza and valuable for pandemics
* More effective vaccines, for example for TB
* More boostable immune responses
* Lower dose is required, reducing costs and time of manufacture, and facilitating storage and logistics issues, etc

Verde Biopharma

Medicinal cannabis is efficient – but hard to administrate – due to the challenges of THC. Verde biopharma is developing a unique set of products for pharmacies, healthcare and personal use that levels the playing field for therapeutic applications of medicinal cannabis, in a safe manner within the guidelines of the newly presented WHO recommendation for a legal rescheduling of cannabis. Our platform allows for greater individualization of medicinal cannabis products for the global market – and a practical solution to many of the challenges of the new market.

PlatOD

Platelets are blood cells which stop bleeding. The only source of platelets for transfusion is from blood donors, but there are issues of shortage, safety and efficacy. PlatOD provides an alternative to platelet transfusion from blood donors, by manufacturing platelets from stem cells using fluidic devices. With its 3 patents and know-how combining physics and biology, PlatOD has a key asset, the short duration of platelet production in its fluidic device. With its must-have technology, addressing the issue of large-scale production, PlatOD will provide the means to produce at a reasonable cost, the large volumes requested for clinical studies. The plan is to develop a pilot in 2 years, with a 4M€-fundraising.

Sumondo

We are developing a device that can help workplaces reduce costs regarding stress-related sick-leave. They can cut sick-leave expenses with 60% and increase work productivity. From our device, the employees get biofeedback and learn what their stress-level is. The management can collect the data and show it on a common dashboard. Interventions should be made and their effect can be measured before and after. We measure 24/7, also during sleep and can give early warnings about emerging toxic, chronic stress, which woul lead to severe illness, long-time absence and inability to work. Our main target are workplaces. A secondary target are hospitals which we can help reduce stress and provide early warnings about severe developments in the patients with cardio-vascular diseases.

Iluria Health

Iluria is a digital health company focusing on ADHD. In a nutshell, we aim to solve the current trial and error ongoing treatment in ADHD patients. We are doing so through an ML based solution which provides on-going, personalized & passive ADHD monitoring, using biomarkers data (wearable agnostic) and AI analysis.

Exploring the Digital Future of Healthcare: Digital Health Investors Panel at RESI Europe

21 Mar

By Karen Deyo, Investor Research Analyst, LSN

Despite the relatively short span of time digital health, as a sector, has been in existence, there has been an explosion in technology and applications in recent years. The increase in digital applications and services, for providers, payers and consumers, is so pronounced, that governments are scrambling to keep up and provide some sort of regulatory framework that can apply to these cutting-edge technologies. From patient disease management to AI-powered diagnostics to EHR management to care coordination, the diversity within digital health can make it difficult to speak to the sector as a whole.

Addressing some of these questions at RESI Europe, the speakers on the Digital Health Investors panel will share their expertise in this area. The panel will take place from 9:00-9:50 AM, and we recommend that anyone interested in an investor’s perspective on the field of digital health attend!

Moderator: Jonas Jendi (Investment Manager, Industrifonden)

Jonas Jendi is an investment manager at Nordic VC Industrifonden (Stockholm), focused on the life science sector. Industrifonden is one of the largest VC funds in the Nordics, focusing on both tech and life science. The €500m evergreen fund invests in early-stage ventures. The Industrifonden life science team currently has a portfolio of 14 companies, from medtech to biotech, both private and publicly traded. Jonas joined Industrifonden in May 2017, bringing onboard recent experience as an independent board member, angel investor and equity analyst. Between 2001 and 2010, Jonas was CEO at Cogmed, a start-up in the field of evidence-based cognitive training (clinically validated software), based in Stockholm and later in the US. Jonas took the company from the research phase at Karolinska Institute in 2001 to acquisition by Pearson in 2010, then managing the Cogmed integration into Pearson. His background also includes strategy work with The Boston Consulting Group.

Lara Koole (Principal, Philips Health Technology Ventures)

Lara leads the European venture capital activities for Philips, includes running the business-independent Philips health technology venture fund focused on investments in early-stage digital health companies to drive strategic value-add relationships with Philips. Looking for driven entrepreneurs that are passionate and capable to address (part of) the quadruple aim in healthcare, improving outcomes and lowering costs while increasing patient and staff satisfaction. Passionate about technology, strategic investing and working together with great teams to scale their companies bringing strategic and industry expertise of Philips to the table.

Tony Chang (Associate, M Ventures)

Tony Chang, PhD, MBA, is an Investment Associate with the New Businesses team at M Ventures. In this role, Tony is focusing on the early stage venture deals in health-tech and digital health, with a particular attention on digital therapeutics deals. Tony has developed substantial experience in assessing digital health deals for both in-clinic and out-of-clinic applications. Prior to M Ventures, Tony was a technology commercialization officer at the University of Western Cape in South Africa where he was responsible for the development of several industry research collaboration and licensing deals. Previously, Tony was a consultant at the strategy practice of EY in Johannesburg.

Thomas Walbert (Digital Health Innovation Manager, weXelerate)

Stephen Kearney is a medical doctor, working with Hannover Re, one of the world’s largest reinsurers. Stephen’s medical speciality is surgery, with experience in academic pathology via lecturing and research, having specialised in cancer genomics and medical informatics. Approximately half of Hannover Re’s business is in the life and health (re)insurance space. Within these verticals, Stephen’s responsibilities include identifying and developing both internal and external innovation opportunities, including in the area of genomics. Besides medicine, Stephen also has academic qualifications and experience in computer science, data analytics and pharmaceutical business, and an undergraduate degree in biochemistry and physics from University College Dublin (UCD).

Stephen Kearney (Innovation – Life & Health, Hannover Re)

Thomas Walbert is the Digital Health Innovation Manager at weXelerate, where he is responsible for building the Health-Cluster program for fostering digital health innovation and managing a network of mentors and experts. Previously, Thomas was a Start-up Consultant at INiTS, a high-tech incubator based in Vienna. He is a start-up enthusiast who is experienced in building environments and networks where corporations and high-tech start-ups can launch revolutionary business models, products, and services.

← Older Entries

%d bloggers like this: